生长激素缺乏症患儿中相关心血管疾病标志物的研究进展

doi:10.11852/zgetbjzz2017-25-12-15

中国儿童保健杂志 ›› 2017, Vol. 25 ›› Issue (12): 1239-1242.DOI: 10.11852/zgetbjzz2017-25-12-15

生长激素缺乏症患儿中相关心血管疾病标志物的研究进展

王盼盼¹, 李艳英², 班博²

1 济宁医学院,山东济宁 272067;
2 济宁医学院附属医院内分泌科,山东济宁 272029

收稿日期:2017-03-16 发布日期:2017-12-10 出版日期:2017-12-10
通讯作者: 班博,E-mail:banbo2011@163.com
作者简介:王盼盼(1990-),女,山东人,硕士研究生,主要研究方向为下丘脑-垂体疾病
基金资助:
山东省济宁市科技发展计划项目(济科字[2015]57号-11)

Research progress on cardiovascular disease markers in children with growth hormone deficiency

WANG Pan-pan¹, LI Yan-ying², BAN Bo²

1 Jining Medical University,Jining,Shandong 272067,China;
2 Department of Endocrinology, Affiliated Hospital of Jining Medical University,Jining,Shandong 272029,China

Received:2017-03-16 Online:2017-12-10 Published:2017-12-10
Contact: BAN Bo,E-mail:banbo2011@163.com

摘要/Abstract

摘要： 生长激素缺乏症(GHD)是指由垂体前叶合成和分泌释放的生长激素(GH)不足,或由于GH分子结构异常等所致的生长发育障碍性疾病。GHD不仅可导致身材矮小、生长缓慢,也可引起各种代谢紊乱。GHD患儿应用基因重组人生长激素(rhGH)治疗不仅能促进其线性生长,也会对相关的心血管疾病(CVD)标志物,如脂质谱、炎性介质、脂肪细胞因子、氧化应激物质、凝血-纤溶系统等生化指标、身体组分及心外膜脂肪组织厚度、颈动脉内膜中层厚度等超声指标产生影响,所有这些因素均参与动脉粥样硬化(AS)过程并可导致CVD的发生。人们对于rhGH的长期安全性问题一直存在争议,近年来,关于GHD患儿应用rhGH治疗前后相关CVD标志物变化的研究也备受关注。

关键词: 生长激素缺乏症, 生长激素, 心血管疾病标志物, 心血管疾病

Abstract: Growth hormone deficiency (GHD) refers to the growth and developmental disorders caused by the lack of growth hormone (GH) released by the anterior lobe synthesis and secretion,or due to abnormal GH molecular structure.Treatment of recombinant human growth hormone (rhGH) in children with GHD not only promotes linear growth,but also affects related cardiovascular disease (CVD) markers such as lipid,inflammatory mediators,fats cytokines,oxidative stress substances,coagulation-fibrinolytic system and other biochemical indicators,body composition and epicardial adipose tissue thickness,carotid intima media thickness and other ultrasonic indicators,all of these factors are involved in atherosclerosis(AS) process and can lead to the occurrence of CVD.In recent years,studies on the changes of related CVD markers before and after rhGH treatment in children with GHD have also been of great concern in the long-term safety of rhGH.

Key words: growth hormone deficiency, growth hormone, cardiovascular disease markers, cardiovascular disease

中图分类号:

R179

王盼盼, 李艳英, 班博. 生长激素缺乏症患儿中相关心血管疾病标志物的研究进展[J]. 中国儿童保健杂志, 2017, 25(12): 1239-1242.

WANG Pan-pan, LI Yan-ying, BAN Bo. Research progress on cardiovascular disease markers in children with growth hormone deficiency[J]. journal1, 2017, 25(12): 1239-1242.

0
/ / 推荐

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://manu41.magtech.com.cn/Jwk_zgetbjzz/CN/10.11852/zgetbjzz2017-25-12-15

https://manu41.magtech.com.cn/Jwk_zgetbjzz/CN/Y2017/V25/I12/1239

参考文献

[1] 王立敏.生长激素缺乏症患儿应用重组人生长激素治疗后内分泌轴的变化[D].济南:山东大学,2015.
[2] Palmeiro CR,Anand R,Dardi IK,et al.Growth hormone and the cardiovascular system[J].Cardiol Rev,2012,20(4):197-207.
[3] Binay C,Simsek E,Yildirim A,et al.Growth hormone and the risk of atherosclerosis in growth hormone-deficient children[J].Growth Horm IGF Res,2015,25(6):294-297.
[4] Meazza C,Elsedfy HH,Pagani S,et al.Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment[J].Horm Metab Res,2014,46(3):219-223.
[5] Choi BJ,Matsuo Y,Aoki T,et al.Coronary endothelial dysfunction is associated with inflammation and vasa vasorum proliferation in patients with early atherosclerosis[J].Arterioscler Thromb Vasc Biol,2014,34(11):2473-2477.
[6] De Leonibus C,De Marco S,Stevens A,et al.Growth hormone deficiency in prepubertal children:predictive markers of cardiovascular disease[J].Horm Res Paediatr,2016,85(6):363-371.
[7] Lopez-Siguero JP,Lopez-Canti LF,Espino R,et al.Effect of recombinant growth hormone on leptin,adiponectin,resistin,interleukin-6,tumor necrosis factor-alpha and ghrelin levels in growth hormone-deficient children[J].J Endocrinol Invest,2011,34(4):300-306.
[8] Roth CL,Reinehr T.Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention[J].Arch Pediatr Adolesc Med,2010,164(2):131-138.
[9] Ruscica M,Baragetti A,Catapano AL,et al.Translating the biology of adipokines in atherosclerosis and cardiovascular diseases:Gaps and open questions[J].Nutr Metab Cardiovasc Dis,2017,27(5):379-395.
[10] Chen C,Jiang J,Lu JM,et al.Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells[J].Am J Physiol Heart Circ Physiol,2010,299(1):H193-H201.
[11] Ciresi A,Pizzolanti G,Leotta M,et al.Resistin,visfatin,leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children[J].J Endocrinol Invest,2016,39(9):1023-1030.
[12] 王全伟 ,凡文博,王智昊,等.氧化应激与心血管疾病关系的研究进展[J].中国老年学杂志,2014,34(1):270-273.
[13] 黄慧琳,葛媛媛,冷吉燕,等.不对称二甲基精氨酸与心血管疾病关系的研究进展[J].中国老年学杂志,2012,32(4):879-881.
[14] De Marco S,Marcovecchio ML,Caniglia D,et al.Circulating asymmetric dimethylarginine and lipid profile in pre-pubertal children with growth hormone deficiency:effect of 12-month growth hormone replacement therapy[J].Growth Horm IGF Res,2014,24(5):216-220.
[15] Onder A,Aycan Z,Koca C,et al.Evaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency[J].J Clin Res Pediatr Endocrinol,2014,6(1):22-27.
[16] Langen J,Kayacelebi AA,Beckmann B,et al.Homoarginine (hArg) and asymmetric dimethylarginine (ADMA) in short stature children without and with growth hormone deficiency:hArg and ADMA are involved differently in growth in the childhood[J].Amino Acids,2015,47(9):1875-1883.
[17] Lanes R.Cardiovascular risk in growth hormone deficiency beneficial effects of growth hormone replacement therapy[J].Endocrinol Metab Clin North Am,2016,45(2):405-418.
[18] Capalbo D,Mattace RG,Esposito A,et al.Cluster of cardiometabolic risk factors in children with GH deficiency:a prospective,case-control study[J].Clin Endocrinol,2014,80(6):856-862.
[19] Canete R,Valle M,Martos R,et al.Short-term effects of GH treatment on coagulation,fibrinolysis,inflammation biomarkers,and insulin resistance status in prepubertal children with GH deficiency[J].Eur J Endocrinol,2012,167(2):255-260.
[20] Cornier MA,Despres JP,Davis N,et al.Assessing adiposity:a scientific statement from the American Heart Association[J].Circulation,2011,124(18):1996-2019.
[21] Khadilkar V,Ekbote V,Kajale N,et al.Effect of one-year growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency[J].Endocr Res,2014,39(2):73-78.
[22] 陈菲,卢岷,冉海涛,等.超声测量心外膜脂肪厚度联合二维纵向应变预测冠状动脉粥样硬化性心脏病[J].中国介入影像与治疗学,2016,13(1):42-46.
[23] Pridavkova D,Kantarova D,Liskova R,et al.The role of epicardial fat and obesity parameters in the prediction of coronary heart disease[J].Vnitr Lek,2016,62(4):256-262.
[24] Lanes R,Soros A,Flores K,et al.Endothelial function,carotid artery intima-media thickness,epicardial adipose tissue,and left ventricular mass and function in growth hormone-deficient adolescents:apparent effects of growth hormone treatment on these parameters[J].J Clin Endocrinol Metab,2005,90(7):3978-3982.
[25] Metwalley KA,Farghaly HS,Abd EH.Evaluation of left ventricular mass and function,lipid profile,and insulin resistance in Egyptian children with growth hormone deficiency:A single-center prospective case-control study[J].Indian J Endocrinol Metab,2013,17(5):876-882.
[26] 杨淑平,梁金文.高敏C反应蛋白及颈动脉内膜中层厚度在急性冠脉综合征患者中的意义[J].中国民康医学,2011,23(16):1981-2061.
[27] Gujral DM,Shah BN,Chahal NS,et al.Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis[J].Radiother Oncol,2016,118(2):323-329.
[28] Capalbo D,Lo VA,Farina V,et al.Subtle alterations of cardiac performance in children with growth hormone deficiency:results of a two-year prospective,case-control study[J].J Clin Endocrinol Metab,2009,94(9):3347-3355.

生长激素缺乏症患儿中相关心血管疾病标志物的研究进展

Research progress on cardiovascular disease markers in children with growth hormone deficiency

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陶佳慧, 陈琳琳, 马钰, 丁琴琴, 王秋晶, 丁文清. 儿童青少年肌肉质量与心血管疾病危险因素的关系[J]. 中国儿童保健杂志, 2022, 30(7): 706-710.
[2]	易晓青, 韩田田, 刘红红, 王思思, 张蓉, 王爱荣, 肖延风. 维生素D和骨形态发生蛋白-2水平与生长激素缺乏症儿童成骨细胞功能的相关性研究[J]. 中国儿童保健杂志, 2021, 29(7): 701-704.
[3]	张甜, 孙海玲, 张梅, 班博, 孙冰. 儿童营养不足与生长激素/胰岛素样生长因子-1相关性研究进展[J]. 中国儿童保健杂志, 2021, 29(7): 734-737.
[4]	万乃君, 张田, 张金, 孙慧慧, 商然, 师伟佳. 长效重组人生长激素治疗儿童生长激素缺乏症的有效性及安全性研究[J]. 中国儿童保健杂志, 2021, 29(7): 755-758.
[5]	杨婷婷, 王佩琪, 赵玲, 刘晓静. Temple综合征1例并文献复习[J]. 中国儿童保健杂志, 2021, 29(6): 694-696.
[6]	朱谦让, 戴月, 张坚, 张静娴, 谢玮. 儿童青少年膳食及血清锌状况与心血管疾病代谢危险因素的关系[J]. 中国儿童保健杂志, 2021, 29(12): 1304-1308.
[7]	曾佩佩, 黄丽萍, 邓梁琼, 冯玉山, 熊莉, 曾婷, 李红辉. 重组人生长激素治疗对特发性矮小症儿童心理状态影响的分析[J]. 中国儿童保健杂志, 2021, 29(1): 71-74.
[8]	祝丹, 余文, 徐健. 腕骨发育评价在青春期前儿童生长激素缺乏症诊断中的参考作用[J]. 中国儿童保健杂志, 2020, 28(7): 733-736.
[9]	刘瑛, 刘翠, 宁静, 郭勇, 吴婕翎. 基于不同体重指数的青春前期生长激素缺乏症患儿采用重组人生长激素治疗的疗效分析[J]. 中国儿童保健杂志, 2020, 28(4): 385-388.
[10]	陈瑾, 陶林辉, 林爱琳, 林蕴. 不同生长激素分泌状态的矮身材儿童25-(OH)D水平的研究[J]. 中国儿童保健杂志, 2020, 28(2): 219-221.
[11]	陈蔚, 贺涛. 单纯性肥胖症儿童血清同型半胱氨酸水平与糖尿病、心血管疾病发生的相关性[J]. 中国儿童保健杂志, 2019, 27(11): 1175-1178.
[12]	彭艳松, 邹芙蓉. 重组人生长激素对青春期前特发性矮身材儿童的生长速率、骨龄的影响及其量效-时效关系[J]. 中国儿童保健杂志, 2019, 27(11): 1228-1231.
[13]	彭艳, 张崇建, 王英, 何志红. 聚乙二醇重组生长激素治疗特发性矮小症儿童效果及对血清p53及p21waf/cip1表达的影响[J]. 中国儿童保健杂志, 2018, 26(6): 587-589.
[14]	潘丹萍, 陆相朋, 段凤阳, 王志如, 姚献花, 马丙祥, 杨艳玲, 郑宏. 神经纤维瘤病Ⅰ型导致的3例身材矮小家系分析[J]. 中国儿童保健杂志, 2018, 26(4): 418-420.
[15]	桂林艳, 王璞. 青春期前特发性矮身材儿童的生长激素应用剂量研究[J]. 中国儿童保健杂志, 2018, 26(4): 451-452.